Related Experiment Video
Updated: Sep 9, 2025
Labeling of Extracellular Vesicles for Monitoring Migration and Uptake in Cartilage Explants
Published on: October 4, 2021
Extracellular vesicles in osteoarthritis: mechanisms, therapeutic potential, and diagnostic applications
Chongxiao Sun1,2,3, Fei Teng1,2,3, Yayi Xia1,2,3
1Department of Orthopaedics, Lanzhou University Second Hospital, Lanzhou, Gansu, China.
Abstract:
Osteoarthritis (OA) is a chronic joint disease characterized by cartilage degradation, inflammation, and bone structural changes, leading to significant disability. Current therapeutic strategies, including traditional treatments and stem cell-based therapies, face limitations such as inability to prevent disease progression, immunogenic rejection, and tumorigenic risks. Extracellular vesicle (EVs), nanoscale membrane-bound vesicles secreted by cells, has emerged as a promising cell-free therapeutic approach due to their low immunogenicity, stability, and ability to mediate intercellular communication. This review summarizes the roles of EVs derived from various cell types, including cartilage progenitor cells (CPCs), bone marrow mesenchymal stem cells (BMSCs), synovial mesenchymal stem cells (SMSCs), adipose-derived stem cells (ADSCs), and immune cells, in OA pathogenesis and treatment. EVs exhibit multifaceted therapeutic potential, including immunomodulation, chondrocyte regeneration, and anti-inflammatory effects. Additionally, EVs serve as diagnostic biomarkers, offering non-invasive early detection of OA. Despite their promise, challenges such as scalability, targeting efficiency, and safety concerns remain. This review highlights the potential of EVs as both therapeutic agents and diagnostic tools, paving the way for innovative OA management strategies.
Insights
Extracellular vesicles (EVs) show promise for treating osteoarthritis (OA) by reducing inflammation and regenerating cartilage. These cell-free therapies also offer potential for early OA diagnosis, overcoming limitations of current treatments.
Area of Science:
- Biomedical Engineering
- Regenerative Medicine
- Cell Biology
Background:
- Osteoarthritis (OA) is a debilitating joint disease with limited treatment options.
- Current therapies for OA, including stem cell treatments, face challenges like immune rejection and safety risks.
- Extracellular vesicles (EVs) offer a promising cell-free therapeutic alternative due to their low immunogenicity and intercellular communication capabilities.
Purpose of the Study:
- To review the role of EVs from various cell sources in osteoarthritis pathogenesis and treatment.
- To explore the therapeutic potential of EVs, including immunomodulation and chondrocyte regeneration.
- To highlight EVs as diagnostic biomarkers for early OA detection.
Main Methods:
- Review of scientific literature on extracellular vesicles and osteoarthritis.
- Analysis of EV functions derived from cartilage progenitor cells (CPCs), mesenchymal stem cells (BMSCs, SMSCs), adipose-derived stem cells (ADSCs), and immune cells.
- Evaluation of therapeutic effects such as immunomodulation, anti-inflammatory actions, and chondrocyte regeneration.
Main Results:
- EVs derived from various stem and immune cells demonstrate significant therapeutic potential in OA models.
- EVs exhibit immunomodulatory, anti-inflammatory, and chondro-regenerative properties.
- EVs show promise as non-invasive biomarkers for early osteoarthritis diagnosis.
Conclusions:
- Extracellular vesicles represent a viable cell-free therapeutic strategy for osteoarthritis, addressing limitations of current treatments.
- EVs hold potential for both treating OA and enabling its early, non-invasive diagnosis.
- Further research is needed to overcome challenges in EV scalability, targeting, and safety for clinical application.
